MLLCFOTCHealthcare · Biotechnology

Molecular Partners AG

$2.55+0.00%(+$0.00)

TickerSpark Score

52/100

Mixed

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLLCF research report →

52-Week Range15% of range

Low $2.25

Current $2.55

High $4.22

Companywww.molecularpartners.com

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers.

CEO: Patrick Amstutz
IPO: 2018
Employees: 158
HQ: Schlieren, CH

Price Chart

-39.57% · this period

Valuation

Market Cap: $95.65M
P/E: -1.89
P/S: 0.00
P/B: 1.60
EV/EBITDA: -0.61
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -66.19%
ROIC: -69.14%

Growth & Income

Revenue: $0 · -100.00%
Net Income: $-61,680,555 · -14.13%
EPS: $-1.65 · -1.23%
Op Income: $-55,461,576
FCF YoY: 16.18%

Performance & Tape

52W High: $4.22
52W Low: $2.25
50D MA: $2.51
200D MA: $3.20
Beta: 1.48
Avg Volume: 29

Get TickerSpark's AI analysis on MLLCF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime